FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2572454942> ?p ?o ?g. }

• W2572454942 abstract "Abstract Abstract 3314 BACKGROUND: For congenital hemophilia patients who develop inhibitors to factors VIII or IX, the management of bleeding episodes can be complex, and often requires use of bypassing agents (BPA) such as rFVIIa (NovoSeven® RT). While some have reported on the variability in responsiveness to BPAs between patients, with the implication that some patients are more or less responsive to particular agents, few trial or registry data sets have sufficient long-term data to capture the intra-patient variability in dosing for specific bleed types or locations to identify if treatment is individualized on a patient basis or instead on a bleed-by-bleed basis by the hematologist and patient/caregiver. The HTRS Registry is a multi-center, longitudinal database of bleeding episodes and treatment patterns for bleeding disorder patients, with a particular focus on the treatment of acute bleeding episodes in inhibitor patients. METHODS: The HTRS registry recorded data between January 2004-March 2011 for 2,053 bleeding episodes in 134 inhibitor patients. From these data, we identified US patients with 75 or more rFVIIa-treated bleeding episodes and analyzed for intra-patient variability using descriptive statistics and graphical representations. RESULTS: 5 patients (3 hemophilia A from 2 centers, 2 hemophilia B from 1 center) were identified with 568 rFVIIa-treated bleeds (28% of total recorded). Patients were White and Non-Hispanic, and ranged in age from 2.2 to 13.7 years old at the time of first reported bleed (2000–2005) and from 6.2 to 17.6 years old at the time of last reported bleed (2004–2008). Patients had 95–162 documented bleeds (mean 113.6) over 38–98 months (mean 62.5), with between 1 and 2.7 bleeds per month (mean 2.0). Median total dose per bleeding episode and interquartile ranges (IQR, 25%-75%) are shown below. Median total dose per episode for all bleeds varied from 570 to 711 mcg/kg, with the minimum reported dose of 50 mcg/kg and maximum of 43,200 mcg/kg. There was some variability but no consistent pattern across patients when comparing median doses for traumatic, spontaneous, joint, muscle and mucosal bleeds. The ratios of IQR/median and range/median total dose were also variable across patients and often across types within patients. The variability in total dose across bleed types/locations can also be demonstrated graphically as in the figures below (patient A, IQR - shaded, median – dotted line). Furthermore, initial doses were consistently above US package insert recommendations of 90 mcg/kg and high initial doses (>250 mcg/kg) were seen throughout 2002–2006. CONCLUSIONS: While registry data are subject to a variety of biases, they are able to capture real world data across patient populations that allows for assessment of variability between patients. In the case of the longstanding HTRS registry, we have the ability to also examine in a limited way differences in dosing within 5 individual patients across a 3–8 year period of childhood and adolescence. Surprisingly, or perhaps not so surprisingly, these exploratory analyses seem to indicate that treatment may be individualized by the hematologist (and hemophilia treatment center) and patient/caregiver for every bleed, and that even in individuals with many spontaneous, traumatic, or joint bleeds, treatment varies between mild bleeds treated with as little as one dose and severe bleeds or surgeries requiring prolonged treatment. Given the challenges of documentation of home treatment within medical records and consequently limited information available for assessment in registries, further analysis of co-variates that can account for these intra-patient variations (e.g. increasing frequency of target joint bleeds, extent of trauma, concurrent activities/sports/camp) will require prospective observational diary or registry studies that can capture additional information. Disclosures: Neufeld: Novo Nordisk Inc.: Consultancy, Research Funding. Off Label Use: rFVIIa (NovoSeven) is approved for the treatment of bleeding episodes in congenital hemophilia with inhibitors; doses shown in this abstract might differ from the US prescribing information. Cooper:Novo Nordisk Inc.: Employment." @default.
• W2572454942 created "2017-01-26" @default.
• W2572454942 creator A5010364362 @default.
• W2572454942 creator A5086220624 @default.
• W2572454942 date "2011-11-18" @default.
• W2572454942 modified "2023-09-28" @default.
• W2572454942 title "Intra-Patient Variability in Recombinant Activated FVII (rFVIIa) Dosing Over 3 to 8 Year Periods in Patients with Congential Hemophilia with Inhibitors Experiencing Frequent Acute Bleeding Episodes: Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry," @default.
• W2572454942 doi "https://doi.org/10.1182/blood.v118.21.3314.3314" @default.
• W2572454942 hasPublicationYear "2011" @default.
• W2572454942 type Work @default.
• W2572454942 sameAs 2572454942 @default.
• W2572454942 citedByCount "0" @default.
• W2572454942 crossrefType "journal-article" @default.
• W2572454942 hasAuthorship W2572454942A5010364362 @default.
• W2572454942 hasAuthorship W2572454942A5086220624 @default.
• W2572454942 hasConcept C126322002 @default.
• W2572454942 hasConcept C141071460 @default.
• W2572454942 hasConcept C187212893 @default.
• W2572454942 hasConcept C2776217217 @default.
• W2572454942 hasConcept C2776259030 @default.
• W2572454942 hasConcept C2777288759 @default.
• W2572454942 hasConcept C2778589496 @default.
• W2572454942 hasConcept C2779134260 @default.
• W2572454942 hasConcept C2908580079 @default.
• W2572454942 hasConcept C3017811039 @default.
• W2572454942 hasConcept C500558357 @default.
• W2572454942 hasConcept C71924100 @default.
• W2572454942 hasConcept C89560881 @default.
• W2572454942 hasConceptScore W2572454942C126322002 @default.
• W2572454942 hasConceptScore W2572454942C141071460 @default.
• W2572454942 hasConceptScore W2572454942C187212893 @default.
• W2572454942 hasConceptScore W2572454942C2776217217 @default.
• W2572454942 hasConceptScore W2572454942C2776259030 @default.
• W2572454942 hasConceptScore W2572454942C2777288759 @default.
• W2572454942 hasConceptScore W2572454942C2778589496 @default.
• W2572454942 hasConceptScore W2572454942C2779134260 @default.
• W2572454942 hasConceptScore W2572454942C2908580079 @default.
• W2572454942 hasConceptScore W2572454942C3017811039 @default.
• W2572454942 hasConceptScore W2572454942C500558357 @default.
• W2572454942 hasConceptScore W2572454942C71924100 @default.
• W2572454942 hasConceptScore W2572454942C89560881 @default.
• W2572454942 hasLocation W25724549421 @default.
• W2572454942 hasOpenAccess W2572454942 @default.
• W2572454942 hasPrimaryLocation W25724549421 @default.
• W2572454942 hasRelatedWork W2035909005 @default.
• W2572454942 hasRelatedWork W2093390545 @default.
• W2572454942 hasRelatedWork W2104229911 @default.
• W2572454942 hasRelatedWork W2131987936 @default.
• W2572454942 hasRelatedWork W2269212930 @default.
• W2572454942 hasRelatedWork W2472787067 @default.
• W2572454942 hasRelatedWork W2501238308 @default.
• W2572454942 hasRelatedWork W2551849694 @default.
• W2572454942 hasRelatedWork W2556576126 @default.
• W2572454942 hasRelatedWork W2563536885 @default.
• W2572454942 hasRelatedWork W2564498386 @default.
• W2572454942 hasRelatedWork W2591893517 @default.
• W2572454942 hasRelatedWork W2595365243 @default.
• W2572454942 hasRelatedWork W2730011131 @default.
• W2572454942 hasRelatedWork W2766908503 @default.
• W2572454942 hasRelatedWork W2969817746 @default.
• W2572454942 hasRelatedWork W2980100372 @default.
• W2572454942 hasRelatedWork W3013565880 @default.
• W2572454942 hasRelatedWork W3097869260 @default.
• W2572454942 hasRelatedWork W3181692457 @default.
• W2572454942 isParatext "false" @default.
• W2572454942 isRetracted "false" @default.
• W2572454942 magId "2572454942" @default.
• W2572454942 workType "article" @default.